Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

PF‐05221304 is a liver‐targeted inhibitor of acetyl‐CoA carboxylase, an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL). This first‐in‐human study investigated safety/tolerability and pharmacokinetics of single and multiple ascending oral PF‐05221304 doses, and fructose‐s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Arthur, Carvajal‐Gonzalez, Santos, Tarabar, Sanela, Saxena, Aditi R., Esler, William P., Amin, Neeta B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317421/
https://www.ncbi.nlm.nih.gov/pubmed/32065514
http://dx.doi.org/10.1002/cpdd.782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317421/
https://www.ncbi.nlm.nih.gov/pubmed/32065514
http://dx.doi.org/10.1002/cpdd.782

Ejemplares similares